The IMPACT2AMR consortium combines the complementary expertise of three highly experienced partners, BioVersys, BioSystems Technology, and Voxcan, to develop novel translational research tools.
The consortium aims to generate a translational research platform to promote the development of antimicrobials and anti-virulence drugs – from the bench to in vivo proof-of-concept.
Current drug discovery tools are inadequate to address MDR/XDR pathogens, requiring development of alternative strategies to be able to explore and target these problematic pathogens. IMPACT2AMR aims to deliver a single research platform that is composed of three independent sub-components, which will be used to expedite development of antimicrobials and novel anti-virulence drugs.
